九旬患者经导管主动脉瓣置换术的长期结局
该研究基于前瞻性机构数据库,比较2011至2018年接受TAVR的八旬与九旬患者长期结局。九旬患者30天、1年、4年生存率与八旬患者无差异,且与年龄性别匹配的美国人群生存相当。TAVR在九旬患者中可安全实施,结局与年轻患者相当并接近自然预期寿命。
要点
- 九旬患者TAVR术后30天、1年、4年生存率与八旬患者无显著差异。
- 九旬患者生存率与年龄性别匹配的美国人群相当。
- 瓣周漏和贫血与TAVR术后1年更差结局相关。
核心结论
- TAVR在九旬患者中可安全实施,结局与年轻患者相当并接近自然预期寿命。
研究设计与样本
- 前瞻性机构数据库识别2011至2018年接受TAVR的八旬和九旬患者,共649例(54.4%)八旬和157例(13.2%)九旬。
- 采用Cox比例风险回归进行基线校正的结局比较和风险预测,并与年龄性别匹配的社会保障精算生命表人群比较生存。
主要发现
- 九旬患者体重指数更低(P < .001)、体表面积更小(P < .001)、慢性阻塞性肺疾病患病率更低(P = .023)但STS评分更高(P < .001)。
- 九旬与八旬患者30天、1年、4年生存率分别为95.5%、80.3%、51.2%与96.9%、87.4%、57.6%,无差异(校正HR 0.8,P = .205)。
- 九旬与八旬患者30天、1年、4年心脏原因再住院率分别为7.9%、25.7%、53.7%与10.3%、27.9%、52.0%,无差异(校正HR 0.9,P = .488)。
- 九旬患者生存与年龄性别匹配的美国人群相当(P = .540)。
- TAVR术后瓣周漏(HR 3.23,P = .042 vs HR 2.66,P = .032)和贫血(HR 0.64,P = .002 vs HR 0.80,P = .004)与1年更差结局相关。
临床怎么用
- 心脏团队应加强TAVR在经良好选择的九旬患者中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has emerged as the preferred alternative to surgical aortic valve replacement in elderly patients. However, the long-term outcomes of nonagenarians undergoing TAVR are unknown. METHODS: Octogenarian and nonagenarian patients undergoing TAVR from 2011 to 2018 were identified from a prospectively maintained institutional database. Cox proportional hazards regression was used for baseline-adjusted outcome comparison and risk prediction. Survival was compared with age and gender-matched population from the Social Security Actuarial Life Table. RESULTS: A total of 649 (54.4%) octogenarians and 157 (13.2%) nonagenarians underwent TAVR. Nonagenarians had a lower body mass index (P < .001), smaller BSA (P < .001), and a lower prevalence of chronic obstructive pulmonary disease (P = .023) but a higher Society of Thoracic Surgeons score (P < .001). The majority of nonagenarians and octogenarians were treated using self-expandable valves (60.3% vs 60.9%; P = .888) via transfemoral access (86.0% vs 81.0%; P = .148). At 30 days, 1 year, and 4 years, there was no difference in survival (95.5%, 80.3%, and 51.2% vs 96.9%, 87.4, and 57.6%, respectively) (adjusted hazard ratio [HR], 0.8; P = .205) and hospital readmissions for cardiac causes (7.9%, 25.7%, and 53.7% vs 10.3%, 27.9%, and 52.0%, respectively) (adjusted HR, 0.9; P = .488). Further, nonagenarians had a survival comparable to an age-matched and sex-matched U.S. population (P = .540). Post-TAVR paravalvular leak (HRs: 3.23 [P = .042] vs 2.66 [P = .032]) and anemia (HRs: 0.64 [P = .002] vs 0.80 [P = .004]) were associated with worse outcomes at 1 year. CONCLUSIONS: TAVR can be performed safely in nonagenarians, with comparable outcomes to younger patients approximating natural life expectancy. This age paradox should strengthen the role of TAVR in well selected nonagenarians by the heart team.
引用
- Habertheuer A, Aranda-Michel E, Schindler J, et al. Longitudinal Outcomes of Nonagenarians Undergoing Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2020. PMID: 32980326. doi:10.1016/j.athoracsur.2020.06.140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。